scout
|Videos|January 21, 2017

Interim Results for Gastric Cancer Treatment With Ramucirumab Plus Pembrolizumab

Author(s)Ian Chau, MD

Ian Chau, MD, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab (Keytruda).

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME